Recently, Neusoft Medical Systems Co., Ltd. (hereinafter referred to as “Neusoft Medicalâ€) announced that it has officially launched 128 rows of Jingrui CT for the global market and exported it to international markets such as South Asia and North Africa. Neusoft has complete independent intellectual property rights. And core technology - previously, this large-scale medical imaging product belonging to the high-end category of the CT market is completely monopolized by multinational medical device companies. "The medical device industry, especially large medical equipment, is a high-tech, high-precision manufacturing industry. Neusoft's previous experience in the software business has greatly helped CT research and development." Liu Jiren, chairman and CEO of Neusoft Group, said . With the breakthrough of this high-end product, the Neusoft medical spin-off and listing plan, which is mainly engaged in research and development of imaging equipment such as CT, has also begun to count down. "Neusoft Medical will complete the spin-off before the end of this year, and the current spin-off work is proceeding in an orderly manner." Liu Jiren revealed on the same day. In December 2014, Neusoft Group announced an agreement with Hongyi Investment, Goldman Sachs, Neusoft Holdings and other investors to invest in Neusoft Medical and Neusoft Xikang – the total investment amount of the two investments is close to RMB 3.8 billion (at the exchange rate on the day of the announcement) ), and become the largest single financing in the domestic medical device field and Internet + medical and health management, and the largest single financing in the global Internet medical and health management field. According to the agreement, after the completion of the delivery of the investment funds, the parties will start the listing process of Neusoft Medical and Neusoft Xikang, and the deadline for completion of the listing is 6 years. Liu Jiren said in an interview with the "First Financial Daily" reporter that this is the first time that Neusoft has introduced strategic investment, and because the group has "further thoughts" on the medical and Xikang business. "Our current goal is to create a way to define a comprehensive health management service. Neusoft Medical can increase the speed of expansion, make existing internationalization more mainstream, and in the Chinese market. Replacing imported equipment.†Zhao Linghuan, the lead investor of the two transactions and the president of Lenovo Hony Capital, said in an interview with China Business News. In 1994, Neusoft Medical developed China's first CT prototype; in 1998, domestic CT was industrialized for the first time under the efforts of Neusoft Medical, which made China the fifth largest CT in the world after the United States, Japan, Germany and Holland. The country of manufacture and export of the whole machine, and caused the average price of imported CT to drop by 20% to 30%. So far, Neusoft Medical's full line of products have passed the ISO9001 international quality system certification, a variety of products have passed the US FDA and European CE certification, providing medical equipment products and services to more than 9,000 medical institutions around the world. "It is estimated that the domestic 128-row CT shipments will reach 40 units in the year, which will break the foreign monopoly of the current high-end CT market. We will optimize the life cycle with better cost performance, speed and performance, and cloud technology applications. Jiang Genmiao, vice president of Neusoft Group and president of Neusoft Medical Systems Co., Ltd., said in an interview with China Business News. It is reported that at the upcoming China's largest medical equipment exhibition in the Asia-Pacific region next week, a number of multinational medical device giants will also release their 128-row CT products, and competition in this field will be further accelerated.
Real Time fluorescence quantitative PCR system is a variation of the standard PCR technique that is commonly used to
Using sequence-specific primers, the number of copies of a particular DNA or RNA sequence can be determined.
By measuring the amount of amplified product at each stage during the PCR cycle, quantification is possible.
pcr equipment, pcr device,rt pcr machine,real-time pcr system,real time pcr instrument Shenzhen Uni-medica Technology Co.,Ltd , https://www.unimed-global.com
quantify DNA or RNA in a sample.